Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
Jennifer J GriggsKari BohlkeEdward P BalabanJames J DignamEvan Thomas HallRobert Donald HarveyDiane P HechtKelsey A KluteVicki A MorrisonT May PiniGary L RosnerCarolyn D RunowiczMichelle ShayneAlex SparreboomSophia TurnerCorrine ZarwanGary H LymanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The Panel continues to recommend that full, weight-based cytotoxic chemotherapy doses be used to treat obese adults with cancer. New to this version of the guideline, the Panel also recommends that full, approved doses of immunotherapy and targeted therapies be offered to obese adults with cancer. In the event of toxicity, the consensus of the Panel is that dose modifications of systemic antineoplastic therapies should be handled similarly for obese and nonobese patients. Important areas for future research include the impact of sarcopenia and other measures of body composition on optimal antineoplastic dosing, and more customized dosing based on pharmacokinetic or pharmacogenetic factors.Additional information is available at www.asco.org/supportive-care-guidelines.
Keyphrases
- weight loss
- body composition
- adipose tissue
- metabolic syndrome
- papillary thyroid
- type diabetes
- obese patients
- end stage renal disease
- bariatric surgery
- squamous cell
- resistance training
- ejection fraction
- childhood cancer
- healthcare
- newly diagnosed
- bone mineral density
- chronic kidney disease
- clinical practice
- oxidative stress
- body mass index
- physical activity
- lymph node metastasis
- peritoneal dialysis
- squamous cell carcinoma
- stem cells
- prognostic factors
- radiation therapy
- current status
- bone marrow
- postmenopausal women
- body weight
- social media
- drug induced
- chronic pain